Literature DB >> 33441535

Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13.

Yan Song1, Ting Du1, Arghya Ray1, Krishan Chauhan2, Mehmet Samur1, Nikhil Munshi1, Dharminder Chauhan3, Kenneth C Anderson4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33441535      PMCID： PMC7806750          DOI： 10.1038/s41408-020-00398-9

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  20 in total

1.  Adrm1, a putative cell adhesion regulating protein, is a novel proteasome-associated factor.

Authors:  Jakob Ploug Jørgensen; Anne-Marie Lauridsen; Poul Kristensen; Karen Dissing; Anders H Johnsen; Klavs B Hendil; Rasmus Hartmann-Petersen
Journal:  J Mol Biol       Date:  2006-06-21       Impact factor: 5.469

2.  Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.

Authors:  N E Franke; D Niewerth; Y G Assaraf; J van Meerloo; K Vojtekova; C H van Zantwijk; S Zweegman; E T Chan; C J Kirk; D P Geerke; A D Schimmer; G J L Kaspers; G Jansen; J Cloos
Journal:  Leukemia       Date:  2011-09-23       Impact factor: 11.528

3.  Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease.

Authors:  Anjli Kukreja; Soroosh Radfar; Ben-Hua Sun; Karl Insogna; Madhav V Dhodapkar
Journal:  Blood       Date:  2009-08-06       Impact factor: 22.113

4.  Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication.

Authors:  W Jiang; D McDonald; T J Hope; T Hunter
Journal:  EMBO J       Date:  1999-10-15       Impact factor: 11.598

Review 5.  Molecular basis of resistance to proteasome inhibitors in hematological malignancies.

Authors:  Denise Niewerth; Gerrit Jansen; Yehuda G Assaraf; Sonja Zweegman; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  Drug Resist Updat       Date:  2014-12-10       Impact factor: 18.500

Review 6.  Therapeutic advances in relapsed or refractory multiple myeloma.

Authors:  Kenneth C Anderson
Journal:  J Natl Compr Canc Netw       Date:  2013-05       Impact factor: 11.908

7.  Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.

Authors:  Ailing Lu; Manuel A Pallero; Weiqi Lei; Huixian Hong; Yang Yang; Mark J Suto; Joanne E Murphy-Ullrich
Journal:  Am J Pathol       Date:  2016-01-20       Impact factor: 4.307

8.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

9.  Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.

Authors:  Y Song; A Ray; S Li; D S Das; Y T Tai; R D Carrasco; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 11.528

10.  A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3.

Authors:  Mylène Tajan; Andreas K Hock; Julianna Blagih; Neil A Robertson; Christiaan F Labuschagne; Flore Kruiswijk; Timothy J Humpton; Peter D Adams; Karen H Vousden
Journal:  Cell Metab       Date:  2018-08-16       Impact factor: 27.287
View more
  2 in total

Review 1.  Genes of the Ubiquitin Proteasome System Qualify as Differential Markers in Malignant Glioma of Astrocytic and Oligodendroglial Origin.

Authors:  Jerry Vriend; Thomas Klonisch
Journal:  Cell Mol Neurobiol       Date:  2022-07-27       Impact factor: 4.231

2.  26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy.

Authors:  Andres J Rubio; Alfonso E Bencomo-Alvarez; James E Young; Vanessa V Velazquez; Joshua J Lara; Mayra A Gonzalez; Anna M Eiring
Journal:  Cells       Date:  2021-09-11       Impact factor: 6.600
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.